Cargando…

Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy

Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell death protein 1 or its ligand 1 (anti-PD-(L)1), has achieved remarkable success in a number of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Lingyue, Huang, Xing, Shi, Fukang, Song, Jinyuan, Guo, Chengxiang, Yang, Jiaqi, Liang, Tingbo, Bai, Xueli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827285/ https://www.ncbi.nlm.nih.gov/pubmed/35139879 http://dx.doi.org/10.1186/s13046-022-02273-w

Ejemplares similares

NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
por: Zhang, Xiaozhen, et al.
Publicado: (2021)

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
por: Zhang, Xiaozhen, et al.
Publicado: (2022)

Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
por: Li, Enliang, et al.
Publicado: (2021)

Protocol for isolating single cells from human pancreatic cancer tissues and analyzing major immune cell populations using flow cytometry
por: Song, Jinyuan, et al.
Publicado: (2023)

Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy
por: Yang, Jiaqi, et al.
Publicado: (2022)

Multiplex imaging reveals the architecture of the tumor immune microenvironment
por: Zhang, Junlei, et al.
Publicado: (2021)

Calreticulin couples with immune checkpoints in pancreatic cancer
por: Huang, Xing, et al.
Publicado: (2020)

Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation
por: Huang, Xing, et al.
Publicado: (2020)

Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix
por: Duan, Yi, et al.
Publicado: (2023)

A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study
por: Huang, Dabing, et al.
Publicado: (2021)

Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
por: Tang, Tianyu, et al.
Publicado: (2022)

Combinational therapy targeting the MET‐mTOR‐ROS loop disrupts mitochondrial autoregulatory machinery of liver cancer
por: Huang, Xing, et al.
Publicado: (2020)

A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma
por: Wang, Junli, et al.
Publicado: (2021)

Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer
por: Yang, Hanshen, et al.
Publicado: (2022)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
por: Boustani, Jihane, et al.
Publicado: (2021)

Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells
por: Lao, Mengyi, et al.
Publicado: (2021)

Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors
por: Bai, Xueli, et al.
Publicado: (2015)

Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
por: Wen, Liang, et al.
Publicado: (2020)

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
por: Huang, Xing, et al.
Publicado: (2020)

Neoadjuvant modified-FOLFIRINOX followed by surgical resection of both the primary and metastatic tumors of a pancreatic hepatoid carcinoma with synchronous liver metastasis: A case report
por: Ma, Tao, et al.
Publicado: (2017)

Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective
por: Huang, Xing, et al.
Publicado: (2020)

Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer
por: Zhang, Qi, et al.
Publicado: (2017)

Oncolytic virotherapy in hepato‐bilio‐pancreatic cancer: The key to breaking the log jam?
por: Li, Yuwei, et al.
Publicado: (2020)

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer
por: Ma, Yangyang, et al.
Publicado: (2023)

Surgical resection and outcome of pancreatic cystic neoplasms in China: analysis of a 16-year experience from a single high-volume academic institution
por: Bai, Xueli, et al.
Publicado: (2014)

Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability
por: Tang, Jianghui, et al.
Publicado: (2023)

Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone conversion surgery
por: Li, Xiang, et al.
Publicado: (2023)

The AKT-independent MET–V-ATPase–MTOR axis suppresses liver cancer vaccination
por: Huang, Xing, et al.
Publicado: (2020)

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
por: Sui, Hongshu, et al.
Publicado: (2018)

Liquid biopsy in pancreatic cancer: the beginning of a new era
por: Yadav, Dipesh Kumar, et al.
Publicado: (2018)

Association of Modified‐FOLFIRINOX‐Regimen‐Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population
por: Li, Xiang, et al.
Publicado: (2018)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy
por: Hu, Jianjun, et al.
Publicado: (2022)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022)

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
por: Tang, Tianyu, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Pancreatic tumor initiation: the potential role of IL-33
por: Huang, Xing, et al.
Publicado: (2021)

Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer
por: Mace, Thomas, et al.
Publicado: (2015)

Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
por: Zhang, Qi, et al.
Publicado: (2020)

Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas
por: Zhang, Qi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_beoukt4qdm05sf096c1tkur64f